Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial

作者：Eunice S. Wang, Ghayas C. Issa, Harry P. Erba, Jessica K. Altman, Pau Montesinos, Stephane DeBotton, Roland B. Walter, Kristen Pettit, Michael R. Savona, Mithun Vinod Shah, Marina Kremyanskaya, Maria R. Baer, James M. Foran, Gary J. Schiller, Lionel Adès, Maël Heiblig, Céline Berthon, Pierre Péterlin, Eduardo Rodríguez‐Arbolí, Olga Salamero, Mrinal M. Patnaik, Cristina Papayannidis, Jolanta Grembecka, Tomasz Cierpicki, Bradley Clegg, Joshua Ray, Brian M. Linhares, Kun Nie, Amitava Mitra, Julie Mackey Ahsan, Marilyn Tabachri, Harris S. Soifer, Daniel Corum, Mollie Leoni, Stephen Dale, Amir T. Fathi · 发表于：The Lancet Oncology · 年份：2024 · DOI：10.1016/s1470-2045(24)00386-3 · 被引用次数：105 · 研究领域：Acute Myeloid Leukemia Research、Chronic Myeloid Leukemia Treatments、Lung Cancer Treatments and Mutations